Enoxaparin Ledraxen® is a high-quality sterile anticoagulant solution manufactured by Venipharm. It contains Enoxaparin Sodium, a Low Molecular Weight Heparin (LMWH) that effectively inhibits clotting factors to prevent and treat thromboembolic disorders. This 8.000 IE (80 mg) presentation is designed for therapeutic dosing in patients requiring intermediate-to-high anticoagulant activity. It is suitable for both subcutaneous and intravenous administration and is supplied in a box of 10 ready-to-use pre-filled syringes, each featuring an integrated safety system for optimal healthcare professional protection.

Key Features and Benefits

• Therapeutic Strength: Each pre-filled syringe delivers exactly 8.000 IE Anti-Xa (80 mg) of Enoxaparin Sodium in a 0.8 ml solution, making it ideal for therapeutic treatment protocols.
• Dual Route of Administration: Formulated for flexible use, indicated for both subcutaneous injection (therapeutic anticoagulation) and intravenous use (for specific procedures including bolus administration).
• Extracorporeal Application: Specifically indicated for use in extracorporeal circuits, particularly the dialysis circuit, to maintain circuit patency during hemodialysis sessions by preventing clot formation.
• Ready-to-Use Precision: The pre-filled format eliminates manual drawing errors, ensures dosing accuracy, and saves valuable clinical time.
• Advanced Safety System: Each syringe is equipped with a passive safety mechanism that activates immediately after injection, shielding the needle to significantly reduce the risk of accidental needle-stick injuries.
• Premium Pharmaceutical Quality: Manufactured by Venipharm, a trusted pharmaceutical company committed to excellence in critical care products.

Indications and Usage
Enoxaparin Ledraxen® (8.000 IE) is primarily indicated for:

• Treatment of Thromboembolism: For the therapeutic management of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients requiring intermediate dosing.
• Extracorporeal Circulation: Prevention of clot formation in the dialysis circuit during hemodialysis procedures.
• Acute Coronary Syndromes: As part of comprehensive management protocols for unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI).
• Perioperative Thromboprophylaxis: In high-risk surgical patients requiring higher anticoagulant coverage.

Important Safety Information
This is a prescription medication intended for hospital or specialized clinical use only. It must be administered under the direct supervision of a qualified healthcare professional experienced in anticoagulant therapy.

• Monitoring: Regular monitoring of platelet counts and signs of bleeding is essential. Patients should be observed for signs of bleeding or unusual bruising.
• Contraindications: Do not use in patients with active major bleeding, history of heparin-induced thrombocytopenia (HIT), recent cerebrovascular hemorrhage, or hypersensitivity to Enoxaparin or heparin derivatives.
• Renal Impairment: Dose adjustment may be required in patients with severe renal impairment.
• Spinal/Epidural Anesthesia: Caution is required due to risk of spinal hematoma when used concomitantly with neuraxial anesthesia.
• Storage: Store below 25°C. Protect from freezing. Keep out of reach of children.

Product Specifications

• Active Ingredient: Enoxaparin Sodium
• Strength: 8.000 IE Anti-Xa (equivalent to 80 mg)
• Volume: 0.8 ml
• Route of Administration: Subcutaneous or Intravenous (Extracorporeal)
• Format: 10 Pre-filled syringes with Integrated Safety System
• Manufacturer: Venipharm

Disclaimer: This description is for informational purposes only and does not constitute medical advice. Always consult the official product leaflet and a qualified healthcare professional for complete prescribing information, contraindications, and proper administration guidelines.